• Ionis announces eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy

    12 days ago - By San Diego Biotechnology

    Eplontersen showed statistically significant and clinically meaningful improvements in mNIS+7 and Norfolk QoL-DN - Eplontersen demonstrated a favorable safety profile - Ionis and AstraZeneca expect to file a New Drug Application this year CARLSBAD,...
    Read more ...